Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been given a consensus rating of “Reduce” by the four brokerages that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $3.00.
PLRX has been the subject of a number of recent research reports. Wall Street Zen cut Pliant Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pliant Therapeutics in a research report on Friday, July 17th.
Check Out Our Latest Stock Analysis on Pliant Therapeutics
Pliant Therapeutics Stock Performance
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Equities analysts forecast that Pliant Therapeutics will post -1.42 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Pliant Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PLRX. Headlands Technologies LLC acquired a new position in Pliant Therapeutics during the second quarter valued at approximately $38,000. Stonepine Capital Management LLC bought a new position in Pliant Therapeutics in the 2nd quarter valued at about $262,813,000. Public Employees Retirement System of Ohio acquired a new stake in Pliant Therapeutics during the 2nd quarter worth approximately $32,000. ADAR1 Capital Management LLC bought a new stake in shares of Pliant Therapeutics in the second quarter valued at about $6,281,000. Finally, Algert Global LLC increased its holdings in shares of Pliant Therapeutics by 46.1% during the second quarter. Algert Global LLC now owns 123,402 shares of the company’s stock worth $141,000 after purchasing an additional 38,950 shares during the period. 97.30% of the stock is owned by institutional investors and hedge funds.
About Pliant Therapeutics
Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.
The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
Featured Stories
- Five stocks we like better than Pliant Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
